Keytruda Leads

Better Than Buying Keytruda Leads

Legal Calls sells exclusive Keytruda injury leads and signed retainers to law firms reviewing individual claims. Claimants allege Keytruda (pembrolizumab) caused severe immune-related injuries such as myocarditis, myositis and myasthenia gravis. Leads come from our own Meta, TikTok and Google ads, are screened in-house, and are delivered by CRM, API, email or warm transfer.

Keytruda Leads & Signed Retainers

Superior Performance, Superior Pricing

To get a Custom Quote Today

Keytruda Leads: Key Facts & Litigation Status

Keytruda Leads at a Glance

Case typePharmaceutical failure-to-warn claims (pembrolizumab), investigation stage
LitigationNo MDL; claims are filed individually against Merck
Alleged injuriesImmune-related myocarditis, myositis, myasthenia gravis; wrongful death
Lead sourcesMeta, TikTok & Google ads — no affiliates
What you getExclusive leads or signed retainers
DeliveryCRM, API, email or warm transfer
IntakeIn-house team, under 1-minute speed-to-lead
ProofTrustedForm certificate, call recordings, ad account access
VolumeOn request
Last reviewedNovember 2026

Keytruda Litigation Status

There is no MDL or other reported consolidated proceeding for Keytruda injury claims as of November 2026. Claims are filed individually and are at an investigation stage. No bellwethers or settlements have been reported.

The notable 2026 case is Dombeck v. Merck, filed August 18, 2026 in the Southern District of Florida. It alleges a 77-year-old melanoma patient died after developing overlapping myocarditis, myositis and myasthenia gravis about 18 days after his first Keytruda dose in 2024. The complaint claims Merck failed to warn of these risks for elderly patients with autoimmune or cardiac history.

In May 2026 the FDA approved a Keytruda label revision adding myocarditis-myositis-myasthenia gravis overlap syndrome to the Warnings and Precautions section on immune-mediated reactions. Plaintiffs are cancer patients, so causation and damages are contested and each case needs individual medical-record review. Separately, the Halozyme v. Merck dispute over subcutaneous Keytruda Qlex is a patent case, not an injury case.

Sources: Keytruda wrongful death lawsuit: Merck failed to warn of fatal immune reactions (AboutLawsuits) · New Lawsuit Says Merck Cancer Drug Keytruda Caused Fla. Man’s Death (HarrisMartin) · FDA supplement approval letter, BLA 125514/S-190 (Keytruda labeling). Status as of November 2026.

What Sets Us Apart From Other Keytruda Lead Vendors?

Years of Excellence
14 +
Ad Spend Managed
78 M+
Leads Delivered
390 k+

Real Customers, Real Satisfaction

Keytruda Client Acquisition Example Criteria & Pricing

Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.

To get a Custom Quote Today

How It Works & Pricing

How Our Keytruda Campaigns Work

  1. We run our own Meta, TikTok and Google ads aimed at Keytruda patients and families affected by severe immune reactions.
  2. Pre-screen questions confirm Keytruda treatment, the immune-related injury and when it began.
  3. Our in-house intake team calls within a minute to confirm hospitalization, outcome and available medical records.
  4. Qualified claimants are delivered to your firm by CRM, API, email or warm transfer, or as signed retainers.

Leads or Signed Retainers — Your Choice

Exclusive Keytruda leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.

Signed Keytruda retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.

Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.

More about Our Keytruda Client Acquisition Signed Retainers

Keytruda Leads: Frequently Asked Questions

Is there an MDL for Keytruda?

No. As of November 2026 Keytruda injury claims are individual lawsuits, and no MDL, class action or state consolidation has been reported. The litigation is best described as an investigation stage.

What injuries qualify?

Firms are reviewing severe immune-related injuries such as myocarditis, myositis and myasthenia gravis, including overlap cases with heart block, kidney injury or death. Each case is evaluated individually.

What is the legal theory?

Failure to warn and negligence: that Merck did not adequately warn of severe immune reactions, especially for elderly patients with autoimmune or cardiac histories. The overlap syndrome was added to the label in May 2026.

Is the Keytruda Qlex lawsuit an injury case?

No. Halozyme v. Merck is a patent dispute over subcutaneous Keytruda Qlex and has nothing to do with patient injuries.

Are your Keytruda leads exclusive?

Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.

Do you sell signed Keytruda retainers?

Yes, for firms that want them. Because there is no MDL, we recommend individual medical-record review on every Keytruda file.

Related Mass Tort Leads

Dupixent Leads · Oxbryta Leads · Depo-Provera Leads · Mass Tort Intake · All mass tort case leads

Are You Price-Shopping for Keytruda Leads?

Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.

Book a time with our VP, and he’ll walk you through pricing and strategy step by step.